DVAX

SCB-2019

COVID-19 Vaccine

Phase 1

Exp Date

August 2020 (Est)

Amp Volatility Score

Catalyst Info & Data Links

Title: COVID-19 Vaccine from Dynavax Phase 1 safety and immunogenicity results


WHAT IS THE NEXT CATALYST EVENT?

  • Preliminary Safety and Immunogenicity results 


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • August 2020 (Est)


PRIOR DATA

PRESS RELEASES


COMPETITORS

MECHANISM OF ACTION

  • CpG 1018 has been studied clinically and developed as a vaccine adjuvant for Dynavax’s hepatitis B vaccine, HEPLISAV-B. The pre-clinical and clinical studies demonstrate that the addition of CpG 1018 increases antibody concentrations, stimulates helper (CD4+) and cytotoxic (CD8+) T cell populations and generates robust T and B cell memory responses.

  • Adjuvants are a pharmacological or immunological substance that is combined with a specific protein (antigen) in a vaccine to help stimulate an immune response against the antigen. Some adjuvants work by stimulating specific immune pathways, such as toll like receptor 9 (TLR9), that promote stronger immune responses than with antigens alone.

  • Combining COVID-19 surface antigens with CpG 1018 for the vaccine to elicit a higher antibody titer. 

  • (Source)

Updated by MV

COVID-19 vaccine, Dynavax, CpG1018, Coronavirus, DVAX

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon